mycosis fungoides

April 18, 2017

Soligenix to Discuss Its Skin Lymphoma Therapy SGX301 at Washington Conference

News

Soligenix will make a presentation in Washington this week on its skin lymphoma treatment SGX301, which benefited 56 percent of patients in a Phase 2 clinical trial. Karen Krumeich, the company’s senior ... Read more

November 15, 2016

FDA Grants Breakthrough Therapy Designation to Adcetris for Certain Lymphoma Subtypes

News

The U.S. Food and Administration (FDA) has granted Breakthrough Therapy Designation to Seattle Genetics’ Adcetris (brentuximab vedotin) as a therapy for the most common subtypes of cutaneous T-cell lymphoma (CTCL), ... Read more

August 3, 2016April 4, 2017

Adcetris Shows Promise in Treating Cutaneous T-Cell Lymphoma in Phase 3 Study

News

Adcetris may greatly benefit patients with cutaneous T-cell lymphoma (CTLC) who received prior systemic or radiation therapy, according to Phase 3 clinical trial results recently announced by Takeda Pharmaceutical Company and Seattle Genetics. The study met ... Read more

July 28, 2016July 28, 2016

Cutaneous T-Cell Lymphoma May Respond Longer to Different Romidepsin Dose Regimen

News

Patients with cutaneous T-cell lymphoma (CTCL) who are treated with romidepsin may have longer response periods with every other week dosing, or even once per month dosing, than with the standard dosing ... Read more

June 15, 2016June 15, 2016

NCCN Releases Informative Guides for Mycosis Fungoides, a Rare Lymphoma

News

To help people with mycosis fungoides, a rare form of non-Hodgkin’s lymphoma, better understand their disease, the National Comprehensive Cancer Network (NCCN) has published two new educational resources: the NCCN Guidelines for Patients ... Read more

March 3, 2016March 3, 2016

Cutaneous T-cell Lymphoma Phase 1 Clinical Trial of MiR-155 Inhibitor Now Enrolling Patients

News

miRagen Therapeutics, Inc., announced that it has started a Phase 1 clinical trial (NCT02580552) of its anti-cancer product candidate MRG-106, a synthetic microRNA antagonist (LNA antimiR) of microRNA-155. The trial’s primary ... Read more